Helicid

Helicid is a pharmaceutical product that contains the active ingredient omeprazole, a proton‑pump inhibitor used to reduce gastric acid. It is marketed in the European Union and is supplied in oral dosage form, though specific strength and tablet or capsule details are not disclosed. As a generic omeprazole, Helicid belongs to the acid‑reducer therapeutic class and works by inhibiting the gastric proton pump in patients with acid‑related disorders.

Helicid (omeprazole) is indicated for several acid‑related gastrointestinal conditions where reduction of gastric secretion is desired.

- Gastro‑oesophageal reflux disease (GERD) and associated heartburn - Erosive oesophagitis confirmed by endoscopy - Healing and maintenance therapy for peptic ulcer disease - Part of combination regimens for Helicobacter pylori eradication - Prevention of gastric ulcer recurrence in patients at risk

Side‑effects reported with Helicid are generally dose‑related and may vary from mild to severe; they are categorized below.

Common: - Headache - Diarrhoea - Nausea or abdominal discomfort

Serious: - Severe allergic reactions (anaphylaxis, angioedema) - Clostridioides difficile‑associated colitis - Low magnesium levels (hypomagnesemia) with prolonged use

Before starting Helicid, clinicians should consider several precautionary factors to ensure safe use.

- Assess renal and hepatic function, especially in patients with severe impairment - Use the lowest effective dose for the shortest duration needed - Evaluate for a history of hypersensitivity to omeprazole or other PPIs - Monitor magnesium levels during long‑term therapy (>1 year) - Consider alternative therapy in patients with known osteoporosis risk - Use caution in pregnancy or lactation when benefit outweighs potential risk

Helicid may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Co‑administration with atazanavir or nelfinavir, which rely on gastric acidity for absorption - Concurrent use with clopidogrel, which may reduce antiplatelet effectiveness - Combination with high‑dose methotrexate, which can increase toxicity

Use with caution: - Drugs metabolized by CYP2C19 (e.g., diazepam, warfarin) may have altered plasma levels - Antifungal agents such as ketoconazole or itraconazole, which need an acidic environment for absorption - HIV protease inhibitors (e.g., lopinavir/ritonavir) where dose adjustments may be needed